Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:REUN

Reunion Neuroscience (REUN) Stock Price, News & Analysis

Reunion Neuroscience logo

About Reunion Neuroscience Stock (NASDAQ:REUN)

Advanced Chart

Key Stats

Today's Range
$1.12
$1.12
50-Day Range
$1.11
$1.13
52-Week Range
$0.63
$5.07
Volume
N/A
Average Volume
210,209 shs
Market Capitalization
$13.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.

Receive REUN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

REUN Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
See More Headlines

REUN Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Reunion Neuroscience investors own include Biora Therapeutics (BIOR), Halliburton (HAL), Meta Platforms (META), Acorda Therapeutics (ACOR), Archer-Daniels-Midland (ADM), Adamis Pharmaceuticals (ADMP) and Applied Genetic Technologies (AGTC).

Company Calendar

Today
4/25/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
NASDAQ:REUN
Employees
16
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-36,690,000.00
Pretax Margin
-2,583.10%

Debt

Sales & Book Value

Annual Sales
$3.88 million
Price / Cash Flow
N/A
Book Value
$1.37 per share
Price / Book
0.82

Miscellaneous

Free Float
N/A
Market Cap
$13.13 million
Optionable
Not Optionable
Beta
2.29
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:REUN) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners